SUVEN — Suven Life Sciences Share News
0.000.00%
Last trade - 00:00- IN₹70.55bn
- IN₹65.54bn
- IN₹71.15m
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees
Brief: Suven Life Sciences Got Tax Order For Demand 17.6 Million Rupees
Brief: Suven Life Sciences Doses First Subjects In Phase-1 Trial Of Suvn-I6107
India's Suven Life doses first subjects in cognitive disorder drug trial; stock up
India's Suven Life Sciences off lows on advancing drug trial after positive results
Brief: Suven Life Sciences To Present Positive Results From Phase-2A Proof-Of-Concept Study Of Ropanicant
India's Suven Life Sciences hits record high on positive drug trial results
Brief: Suven Life Sciences Announces Positive Results From Phase-2A Study Of Suvn-911
India's Suven Life hits record high on US FDA nod for dementia drug trial
Brief: Suven Life Sciences Re- Appoints Venkateswarlu Jasti As MD
India's Suven Pharma, Cohance merge to boost contract drug manufacturing services
India's Suven Pharma rallies to over 1.5-yr high
Brief: Suven Life Sciences Says Positive Topline Results From A Phase-2 Study Evaluating Samelisant Excessive Daytime Sleepiness
Li & Fung considers options for $500 mln Asia healthcare arm, including a sale - sources
Advent to buy 'significant' stake in India's Suven Pharma, explore merger (updated)
Brief: Suven Life Sciences Rights Issue To Open On Oct 31, Close On Nov 10